HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.8%

Neg 0% Neu 90.8% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.